Shandong Xinhua Pharmaceutical Company Limited (“Xinhua Pharmaceutical”) announced that it has secured a Drug Registration Certificate (National Medicine Zhunzi H20263780) from China’s National Medical Products Administration for its Sodium Potassium Magnesium and Calcium Concentrated Solution for Injection.

The 20 ml prescription-only product, classified as a Class 3 chemical, is indicated for electrolyte supplementation during central venous infusion of concentrated glucose or amino-acid solutions in adult patients, helping maintain electrolyte homeostasis. There is no current imported equivalent, and no domestic manufacturer has yet launched the product commercially, positioning Xinhua Pharmaceutical as an early entrant.

The filing follows a July 2024 agreement under which Beijing Minkang Baicao Pharmaceutical Technology transferred full Marketing Authorization Holder rights—including manufacturing and commercialization—to Xinhua Pharmaceutical for an undisclosed, milestone-based technology transfer fee. The transaction did not require board or shareholder approval and does not qualify as a major asset restructuring under Shenzhen Stock Exchange rules.

Management expects the new approval to expand the company’s formulation portfolio and enhance market competitiveness. However, the company cautions that sales performance will depend on domestic pharmaceutical policy shifts, procurement dynamics and broader market conditions, all of which introduce uncertainty for future revenue contributions.